Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetic Study of NPT 2042 in Healthy Adults
NCT05503511Phase 1Completed
- Sponsor
- NeuroPro Therapeutics
- Start
- Oct 2022
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of NPT-2042 in epilepsy (6 cohorts), sponsored by NeuroPro Therapeutics. Primary endpoints: Number of participants with adverse events up to 11 days, Number of participants with abnormal lab test results up to 11 days and 2 more. Started Oct 2022; status: completed.
02
Drugs
NPT-2042
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT05503511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05503511.